STROBE Statement—Checklist of items that should be included in reports of

No Recommendation
Title and 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract
abstract menunjukan desain penelitian dengan istilah yang umum digunakan dalam judul atau abstrak

(b) Provide in the abstract an informative and balanced summary of what was done
and what was found
abstrak memberikan ringkasan yang informatif dan seimbang tentang apa yang telah dilakukan
dan apa yang ditemukan

Introduction
Background/r 2 Explain the scientific background and rationale for the investigation being reported
ationale terdapat penjelasan latar belakang ilmiah dan alasan penyelidikan ada pada background

Objectives 3 State specific objectives, including any prespecified hypotheses

menyatakan tujuan khusus, termasuk hipotesis yang ditentukan sebelumnya

Methods
Study design 4 Present key elements of study design early in the paper
menyebutkan key elements of study design early di awal artikel

Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment,
exposure, follow-up, and data collection
menjelaskan tentang pengaturan, lokasi dan tanggal, termasuk saat pengrekrutan, pemaparan,
follow up, dan pengambilan data

Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants.
Describe methods of follow-up
memberikan kriteria kelayakan, dan sumber serta metode penetapan kasus
dan pemilihan kontrol. memberikan alasan untuk pemilihan kasus dan kontrol
 (b) For matched studies, give matching criteria and number of exposed and unexposed
Untuk studi yang cocok, memberikan kriteria yang cocok dan jumlah kontrol per kasus

Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.
Give diagnostic criteria, if applicable
menentukan dengan jelas semua hasil, eksposur, prediktor, pembaur potensial, dan efek
pengubah. memberikan kriteria diagnostik, jika ada

Data sources/ 8* For each variable of interest, give sources of data and details of methods of assessment
(measurement). Describe comparability of assessment methods if there is more than one group
measurement
Bias 9 Describe any efforts to address potential sources of bias ⊠
menjelaskan setiap upaya untuk mengatasi potensi sumber bias

Study size 10 Explain how the study size was arrived at ⊠

menjelaskan bagaimana ukuran penelitian ditentukan

Quantitative 11 Explain how quantitative variables were handled in the analyses. If applicable,
variables describe which groupings were chosen and why
dijelaskan bagaimana variabel kuantitatif ditangani dalam analisis. Jika berlaku,
menggambarkan pengelompokan mana yang dipilih dan mengapa
Statistical 12 (a) Describe all statistical methods, including those used to control for confounding
methods menjelaskan semua metode statistik, termasuk yang digunakan untuk mengontrol perancu

(b) Describe any methods used to examine subgroups and interactions

menjelaskan metode yang digunakan untuk memeriksa sub kelompok dan interaksi

(c) Explain how missing data were addressed ⊠

menjelaskan bagaimana data yang hilang ditangani
A month after the follow-up date, a weekly reminder through text
message or telephone was sent if the patient did not fill out the online
questionnaire.
(d) If applicable, explain how loss to follow-up was addressed ⊠
Jika bisa, penjelasan bagaimana pencocokan kasus dan kontrol ditangani
The follow-up assessments were conducted for the first and second
years after the ACLR through an online questionnaire sent to the
e-mail addresses of patients. A month after the follow-up date, a
weekly reminder through text message or telephone was sent if the
patient did not fill out the online questionnaire.
(e) Describe any sensitivity analyses

Results
Participants 13 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,
* examined for eligibility, confirmed eligible, included in the study,
completing follow-up, and analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive 14 (a) Give characteristics of study participants (eg demographic, clinical, social) and
data * information on exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Summarise follow-up time (eg, average and total amount)
Outcome data 15 Report numbers of outcome events or summary measures over time
*
 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
precision (eg, 95% confidence interval). Make clear which confounders were
adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a
meaningful time period
Other 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
analyses analyses

Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision.
Discuss both direction and magnitude of any potential bias

Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
of analyses, results from similar studies, and other relevant evidence

Generalisability 21 Discuss the generalisability (external validity) of the study results

Other
information
 Funding 22 Give the source of Give the source of funding and the role of the funders for the present study
and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological
background and published examples of transparent reporting. The STROBE checklist is best used in
conjunction with this article (freely available on the Web sites of PLoS Medicine at
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at
http://www.epidem.com/). Information on the STROBE Initiative is available at
http://www.strobe-statement.org.